Closed loop insulin delivery: current status of diabetes technologies and future prospects.

Closed loop insulin delivery: current status of diabetes technologies and future prospects. Expert Rev Med Devices. 2018 Jul 20;: Authors: Majeed W, Thabit H Abstract INTRODUCTION: Type 1 diabetes is characterised by destruction of pancreatic beta cells, leading to insulin deficiency and hyperglycaemia. The mainstay of treatment remains lifelong insulin therapy as a sustainable cure has as yet proven elusive. The burden of daily management of type 1 diabetes has contributed to suboptimal outcomes for people living with the condition. Innovative technological approaches have been shown to improve glycaemic and patient-related outcomes. Areas covered: We discuss recent advances in diabetes technologies in type 1 diabetes and the 'artificial pancreas', also known as closed-loop systems. its various components, technical aspects and limitations are reviewed. We also discuss its advent into clinical practise, and other systems in development. Evidence from clinical studies are summarised. Expert commentary: The recent approval of a hybrid closed-loop system for clinical use highlights the significant progress made in this field. Results from clinical studies have shown safety and glycaemic benefit, however challenges remain around improving performance and acceptability. More data is required to establish long-term clinical efficacy and cost-effectiveness, to fulfil the expectations of people with type 1 diabetes. PMID: 30027775 [...
Source: Expert Review of Medical Devices - Category: Medical Devices Tags: Expert Rev Med Devices Source Type: research